Thoraxeditorial by Jenkins and Beasley related to tiotropium respimat
نویسندگان
چکیده
منابع مشابه
Thorax editorial by Jenkins and Beasley related to tiotropium respimat.
We thank Drs Jenkins and Beasley for their comments in the recent editorial regarding tiotropium (SPIRIVA). Preceding the Singh et al analysis cited by the authors, Boehringer Ingelheim (BI) had analysed both the tiotropium HandiHaler and Respimat pooled datasets using patient-level data on-treatment as well as including vital status. The results showed a nominally statistically significant red...
متن کاملTiotropium Bromide/Olodaterol (Stiolto Respimat)
INTRODUCTION Chronic obstructive pulmonary disease (COPD), a relatively common respiratory disorder in the U.S., is the third leading cause of death in this country.1 It has been estimated that 15 million Americans have COPD.1 Since the disorder is so common, effective treatment regimens are a prominent research topic in pharmacology. Still, the development of pharmacological treatments for COP...
متن کاملTiotropium Respimat increases the risk of mortality.
In the 10 years since tiotropium was introduced into clinical practice, it has become the mainstay long-acting bronchodilator for maintenance treatment in Chronic Obstructive Pulmonary Disease (COPD). Multiple randomised controlled trials have demonstrated its efficacy as an intervention which improves lung function, quality of life, symptom control and exercise capacity, and reduces exacerbati...
متن کاملTiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis
INTRODUCTION Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (COPD) and delivered via HandiHaler(®) (18 μg once daily) or Respimat(®) Soft Mist™ inhaler (5 μg once daily). The recent TIOtropium Safety and Performance In Respimat(®) (TIOSPIR™) study demonstrated that both exhibit similar safety profiles. This analysis provides an updated comprehensive safety e...
متن کاملTiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
AIM This observational study with tiotropium Respimat® was performed in a real-life setting to investigate its effectiveness with regard to physical functioning and tolerability. METHODS Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 65.5 years) received tiotropium 5 μg once daily via Respimat® Soft Inhaler for 6 weeks in an open-label observational study. At ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thorax
سال: 2013
ISSN: 0040-6376,1468-3296
DOI: 10.1136/thoraxjnl-2013-203228